Watch our Latest Webinar: "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery"

Pharma Services

InterVenn’s biomarker discovery platform, GlycoVision™, decodes a previously untapped layer of biology: the glycoproteome. Critical insights into cellular and protein function are achieved through the characterization of glycoproteins. 

Contact us to partner

We're Unlocking Novel Disease Insights into the Glycoproteome

Historically, the complexity of data generated using mass spectrometry had made it virtually impossible to study the glycoproteome of at scale. Using artificial intelligence and machine learning to accelerate data processing, GlycoVision has overcome this barrier and is generating crucial information that is missing from the existing -omics landscape.


GlycoVision is the first commercially available glycoproteomic platform that enables the generation of new disease insights and the discovery of a robust pipeline of biomarkers for early disease detection, response prediction, disease prognosis, and therapeutic monitoring. Together we can discover a spectrum of novel, high-performing biomarkers to revolutionize our understanding of disease pathways and therapeutic response.


GlycoVision detects approximately 700 of the most highly abundant glycoisoforms found in blood with well-established disease involvement. The platform generates fast and reproducible results to help select patients for clinical trials, monitor efficacy of therapy, and enable new drug target identification.

Our technology does not depend on biomarkers that are produced by a tumor; instead, it relies on an amplification orchestrated by the highly sensitive host immune system, enabling detection at the earliest stages of disease.

Biomarker Discovery and Validation

Choose an unbiased or targeted approach.

Pathway Analysis

Discover new insights into biomarker-related pathways.

Patient Stratification

Stratify patients with response prediction, prognosis, and monitoring.

Clinical Trial Design Support

Insights into clinical trial design, patient selection, and other clinical endpoints.

GlycoVision Knowledge Graph

Discover key connections in your drug pathway with our knowledge graph

InterVenn has created the first knowledge graph of its kind, combining InterVenn’s glycoproteomic data along with highly curated, public datasets (genomics, proteomics, pathways, publications, and clinical trials) to provide unique insights on disease related pathways.

A better understanding of the relationships between -omics data will help explain why certain patients respond better than others to a drug, provide hypotheses that support new treatment combinations and lead to the identification of new therapeutic targets.

The knowledge graph will enable you to further uncover the complexity of human biology.

Start Your Project Today

Our Process

InterVenn has developed a complete glycoproteomic solution: our scientists work hand in hand with your team all the way from study design to analysis and data interpretation.

less than


required per sample


Multiple sample types accepted: serum, plasma, or tissue


Discoveries can be transferred to our CLIA lab environment


Run discovery profile or take a targeted approach


Demonstrated high level of sensitivity across a diversity of applications and disease states (oncology, autoimmune and infectious)

Accessioning and Extraction

Sample Preparation and Enzymatic Digestion

Separation and Identification by Liquid Chromatography-Mass Spectrometry (LC-MS)

Proprietary AI & Machine Learning


Clinical Evidence Powered by GlycoVision


Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Front. Immunol., 13 June 2023 | Sec. Cancer Immunity and Immunotherapy | Volume 14 - 2023

Immune checkpoint inhibitors are effective treatments for advanced or metastatic melanoma, but not all patients show durable response.

Compared to prior studies, like the one seen in Figure 1, we improved separation and ability to select patients who will benefit from IO.

Figure 1. Journal of Clinical Oncology 2022 40:16_suppl, 9522-9522

Likely to Benefit
Unlikely to Benefit

Classifier prediction Events/N Median OS (Months) HR (95% CI) P-value
Discovery cohort (n=202)
Likely to benefit92/17954.3 (37.9, NR) Reference
Unlikely to benefit21/233.7 (2.4, 10.8) 5.1 (3.1, 8.4)7.6×10-11
Independent validation cohort (n=27)
Likely to benefit6/23NR (15.8, NR)Reference
Unlikely to benefit3/46.0 (2.4, NR)5.6 (1.2, 25.5)0.027

We have identified biomarkers that can predict which patient populations are likely or unlikely to benefit from anti-PD-1 monotherapy or anti-CTLA-4/PD-1 combination therapy.

The initial model was developed using a discovery cohort of 202 patients recruited as part of studies conducted at the Massachusetts General Hospital (MGH). These patients had metastatic melanoma treated with first or second-line anti-PD-1 monotherapy or anti-PD-1/anti-CTLA-4 combination therapy.

The model was further tested with an independent validation cohort to confirm the performance characteristics of the classifier. This cohort of 27 patients was recruited as part of studies conducted at Royal Adelaide Hospital. The cohort included patients with metastatic melanoma treated with first or second-line anti-PD-1 monotherapy (pembrolizumab or nivolumab) or anti-PD-1/anti-CTLA-4 combination therapy (nivolumab/ipilimumab).

Featured Publications

Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling


Read Paper

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Life Science Alliance

Read Paper

Novel plasma glycoprotein biomarkers predict progression-free survival in surgically resected clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Read Paper

Disease Areas Yielding Significant Results

Response to Immune Checkpoint Inhibitors

Esophageal (ESCC)
Metastatic Melanoma
ccRenal Cell Carcinoma


ccRenal Cell Carcinoma

Cancer Diagnosis

Bone and soft tissue
Nasopharyngeal cancer

Autoimmune Disease Dx

Infectious Disease Dx/ Px


Immune aging
Gestational age


Why Study Glycoproteomics?

Glycoproteomics provides a unique perspective by defining the roles of glycosylation in regulating health and disease. It complements other -omics by contributing detailed information about protein modifications that critically influence protein function and stability, offering insights into disease mechanisms that are not apparent through other -omics analyses alone.

The integration of data from various -omics fields, including glycoproteomics, is a powerful approach for obtaining a comprehensive understanding of biological systems.

Contact Our Pharma Services Team to Discuss Your Project


By clicking submit, you confirm that you are a U.S. resident and you agree to receive information about InterVenn, including information about any of its current or future products or product candidates or disease state information, and you acknowledge that you have read and agree to the Terms of Use and Privacy Policy. All personal information will be kept confidential and will not be shared with any parties other than InterVenn, its affiliates and their designated agents.

View our privacy policy.

Get in touch